The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)
Phase 2
Terminated
- Conditions
- Middle Cerebral Artery Stroke
- Registration Number
- NCT00401310
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The safety and efficacy of MK0724 will be assessed in patients with acute middle cerebral artery stroke using the Action Reach Arm Test (ARAT). This test allows measurement of a specific functional deficit and subsequent recovery correlating with the specific area of stroke in the brain.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- 18-80 yrs of age inclusive
- Patient is able to receive IV infusion 8-36 hours after stroke onset
- Baseline NIHSS of 6-18 inclusive
Read More
Exclusion Criteria
- Patient had another stroke within 3 months preceding current stroke, patient's stroke is of origin other than MCA (e.g., non-ischemic, hemorrhage), significant cerebral edema, abnormal liver enzymes and abnormal renal and hepatic functions
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Action Research Arm Test score At 90 days
- Secondary Outcome Measures
Name Time Method Scores on the Stroke Arm Strength question, modified Rankin, and Barthel Index. At 90 days